WO2002040478A1 - Composes dihalogenes - Google Patents
Composes dihalogenes Download PDFInfo
- Publication number
- WO2002040478A1 WO2002040478A1 PCT/JP2001/010086 JP0110086W WO0240478A1 WO 2002040478 A1 WO2002040478 A1 WO 2002040478A1 JP 0110086 W JP0110086 W JP 0110086W WO 0240478 A1 WO0240478 A1 WO 0240478A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- cyclopropyl
- carbon atoms
- fluoro
- dihydro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 227
- 150000003839 salts Chemical class 0.000 claims abstract description 115
- 125000001424 substituent group Chemical group 0.000 claims abstract description 86
- 150000004677 hydrates Chemical class 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 31
- 125000004432 carbon atom Chemical group C* 0.000 claims description 135
- -1 acetyloxymethyl Chemical group 0.000 claims description 110
- 125000000217 alkyl group Chemical group 0.000 claims description 90
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 60
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 32
- 125000003277 amino group Chemical group 0.000 claims description 31
- 125000001153 fluoro group Chemical group F* 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 229910052731 fluorine Inorganic materials 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 14
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 108010016626 Dipeptides Proteins 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 208000035473 Communicable disease Diseases 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 8
- 230000036961 partial effect Effects 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 claims description 6
- 125000004849 alkoxymethyl group Chemical group 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 28
- 229940079593 drug Drugs 0.000 abstract description 20
- 241000894006 Bacteria Species 0.000 abstract description 14
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical class C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 abstract description 11
- 241000192125 Firmicutes Species 0.000 abstract description 9
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 102100025142 Beta-microseminoprotein Human genes 0.000 abstract 1
- 101100185029 Homo sapiens MSMB gene Proteins 0.000 abstract 1
- 206010041925 Staphylococcal infections Diseases 0.000 abstract 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 195
- 230000002829 reductive effect Effects 0.000 description 165
- 239000000243 solution Substances 0.000 description 162
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 156
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 136
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 122
- 238000006243 chemical reaction Methods 0.000 description 111
- 239000000203 mixture Substances 0.000 description 111
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 109
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 99
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 96
- 238000001816 cooling Methods 0.000 description 86
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 75
- 238000001914 filtration Methods 0.000 description 73
- 239000012044 organic layer Substances 0.000 description 70
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 68
- 239000007864 aqueous solution Substances 0.000 description 67
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 63
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 60
- 239000000706 filtrate Substances 0.000 description 52
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- 239000013078 crystal Substances 0.000 description 49
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 49
- 238000003756 stirring Methods 0.000 description 47
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
- 238000005481 NMR spectroscopy Methods 0.000 description 41
- 239000002904 solvent Substances 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- 239000003921 oil Substances 0.000 description 37
- 229910052739 hydrogen Inorganic materials 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 238000002844 melting Methods 0.000 description 31
- 230000008018 melting Effects 0.000 description 31
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- 239000002253 acid Substances 0.000 description 28
- 239000010410 layer Substances 0.000 description 26
- 239000000843 powder Substances 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- 238000010898 silica gel chromatography Methods 0.000 description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000012299 nitrogen atmosphere Substances 0.000 description 21
- 238000010992 reflux Methods 0.000 description 21
- 238000005406 washing Methods 0.000 description 21
- 230000002378 acidificating effect Effects 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 238000001953 recrystallisation Methods 0.000 description 18
- 235000008504 concentrate Nutrition 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- 238000001035 drying Methods 0.000 description 15
- 125000006239 protecting group Chemical group 0.000 description 15
- 239000006188 syrup Substances 0.000 description 15
- 235000020357 syrup Nutrition 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 13
- 239000002274 desiccant Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 238000000921 elemental analysis Methods 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 150000007660 quinolones Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QJTCVIHNVLALCL-SECBINFHSA-N tert-butyl n-[1-[(3r)-pyrrolidin-3-yl]cyclopropyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1([C@H]2CNCC2)CC1 QJTCVIHNVLALCL-SECBINFHSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 238000004237 preparative chromatography Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 101100274581 Caenorhabditis elegans chc-1 gene Proteins 0.000 description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 206010028470 Mycoplasma infections Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 4
- 229940124350 antibacterial drug Drugs 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 4
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010039438 Salmonella Infections Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 3
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 description 3
- 201000003146 cystitis Diseases 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229960003376 levofloxacin Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical class C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 3
- 206010039447 salmonellosis Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- VHUSJZPIQCMYND-SNVBAGLBSA-N tert-butyl n-methyl-n-[1-[(3r)-pyrrolidin-3-yl]cyclopropyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)C1([C@H]2CNCC2)CC1 VHUSJZPIQCMYND-SNVBAGLBSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- TUKJTSUSKQOYCD-STHAYSLISA-N (1r,2s)-2-fluorocyclopropan-1-amine Chemical compound N[C@@H]1C[C@@H]1F TUKJTSUSKQOYCD-STHAYSLISA-N 0.000 description 2
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 2
- RVDLHGSZWAELAU-UHFFFAOYSA-N 5-tert-butylthiophene-2-carbonyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)S1 RVDLHGSZWAELAU-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003754 Atypical mycobacterial infections Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000005973 Carvone Substances 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061190 Haemophilus infection Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- SPLNGOFULBNITO-UHFFFAOYSA-N O=C1C(C(O)=O)C=NC2=C1C=CC=C2OC Chemical compound O=C1C(C(O)=O)C=NC2=C1C=CC=C2OC SPLNGOFULBNITO-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OFHVHNZTMIEBHO-SNVBAGLBSA-N tert-butyl n-[1-[(3r)-pyrrolidin-3-yl]cyclobutyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1([C@H]2CNCC2)CCC1 OFHVHNZTMIEBHO-SNVBAGLBSA-N 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- ZFYIQPIHXRFFCZ-QMMMGPOBSA-N (2s)-2-(cyclohexylamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC1CCCCC1 ZFYIQPIHXRFFCZ-QMMMGPOBSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- OFMRACCIIIDSDN-UHFFFAOYSA-N 1,2,4-trichloro-3,5-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(Cl)C([N+]([O-])=O)=C1Cl OFMRACCIIIDSDN-UHFFFAOYSA-N 0.000 description 1
- JIOYLBIVCRZUEQ-UHFFFAOYSA-N 1-acetylcyclopropane-1-carboxylic acid Chemical compound CC(=O)C1(C(O)=O)CC1 JIOYLBIVCRZUEQ-UHFFFAOYSA-N 0.000 description 1
- OKGHUXJLDXCNGS-UHFFFAOYSA-N 1-cyclopropylpyrrolidine Chemical compound C1CC1N1CCCC1 OKGHUXJLDXCNGS-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- ALLSOOQIDPLIER-UHFFFAOYSA-N 2,3,4-trichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(Cl)=C1Cl ALLSOOQIDPLIER-UHFFFAOYSA-N 0.000 description 1
- WEPXLRANFJEOFZ-UHFFFAOYSA-N 2,3,4-trifluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1F WEPXLRANFJEOFZ-UHFFFAOYSA-N 0.000 description 1
- OCJDCFUHHBCTFI-UHFFFAOYSA-N 2,4-difluoro-3-methylbenzoic acid Chemical compound CC1=C(F)C=CC(C(O)=O)=C1F OCJDCFUHHBCTFI-UHFFFAOYSA-N 0.000 description 1
- NJYBIFYEWYWYAN-UHFFFAOYSA-N 2,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1F NJYBIFYEWYWYAN-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- XGLVDUUYFKXKPL-UHFFFAOYSA-N 2-(2-methoxyethoxy)-n,n-bis[2-(2-methoxyethoxy)ethyl]ethanamine Chemical compound COCCOCCN(CCOCCOC)CCOCCOC XGLVDUUYFKXKPL-UHFFFAOYSA-N 0.000 description 1
- MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical compound CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- NKNBYFBSHOGEKE-UHFFFAOYSA-N 3-(dimethylamino)prop-2-enoic acid Chemical compound CN(C)C=CC(O)=O NKNBYFBSHOGEKE-UHFFFAOYSA-N 0.000 description 1
- JSGVZVOGOQILFM-UHFFFAOYSA-N 3-methoxy-1-butanol Chemical compound COC(C)CCO JSGVZVOGOQILFM-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- KOAWAWHSMVKCON-UHFFFAOYSA-N 6-[difluoro-(6-pyridin-4-yl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1C(F)(F)C(N1N=2)=NN=C1C=CC=2C1=CC=NC=C1 KOAWAWHSMVKCON-UHFFFAOYSA-N 0.000 description 1
- AXPYHBDAAGVBAW-UHFFFAOYSA-N 7-[3-(1-aminoethyl)pyrrolidin-1-yl]-2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1C(C(N)C)CCN1C1=CC=C(C=C(C(O)=O)C(=O)N2)C2=C1 AXPYHBDAAGVBAW-UHFFFAOYSA-N 0.000 description 1
- MLJBZCFQFLIEMD-UHFFFAOYSA-N 7-[3-(aminomethyl)pyrrolidin-1-yl]-2-oxo-1h-quinoline-3-carboxylic acid Chemical class C1C(CN)CCN1C1=CC=C(C=C(C(O)=O)C(=O)N2)C2=C1 MLJBZCFQFLIEMD-UHFFFAOYSA-N 0.000 description 1
- ASWWZZZYIWTXDH-UHFFFAOYSA-N 8-methyl-3H-quinolin-4-one Chemical compound CC=1C=CC=C2C(CC=NC=12)=O ASWWZZZYIWTXDH-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010048946 Anal abscess Diseases 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- STHHPVHLWNXLHM-UHFFFAOYSA-M C(=O)O.C(C1=CC=CC=C1)O[Cr](=O)(=O)O Chemical compound C(=O)O.C(C1=CC=CC=C1)O[Cr](=O)(=O)O STHHPVHLWNXLHM-UHFFFAOYSA-M 0.000 description 1
- CRJPCFXDUJZWOJ-UHFFFAOYSA-M C(CC(=O)[O-])(=O)OCC.[Mg+] Chemical compound C(CC(=O)[O-])(=O)OCC.[Mg+] CRJPCFXDUJZWOJ-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- CTZHXEOAVHVLCX-UHFFFAOYSA-N F.F.F.C1CCOC1 Chemical compound F.F.F.C1CCOC1 CTZHXEOAVHVLCX-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 201000003641 Glanders Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010056254 Intrauterine infection Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241001634097 Lilium lankongense Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 208000009019 Pericoronitis Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000365689 Pudu Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010042343 Subcutaneous abscess Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- FKCBLVCOSCZFHV-UHFFFAOYSA-N acetonitrile;ethanol Chemical compound CCO.CC#N FKCBLVCOSCZFHV-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000006231 alkoxy propyl group Chemical group 0.000 description 1
- 125000004848 alkoxyethyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- ZXVOCOLRQJZVBW-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000006630 butoxycarbonylamino group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical group [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate trihydrate Substances [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010062952 diffuse panbronchiolitis Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FCYVHOYOPMGATN-UHFFFAOYSA-N ethyl 1-(2-bromoacetyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(C(=O)CBr)CC1 FCYVHOYOPMGATN-UHFFFAOYSA-N 0.000 description 1
- MVUMJYQUKKUOHO-UHFFFAOYSA-N ethyl 3-(dimethylamino)prop-2-enoate Chemical compound CCOC(=O)C=CN(C)C MVUMJYQUKKUOHO-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- FRIPRWYKBIOZJU-UHFFFAOYSA-N fluorone Chemical compound C1=CC=C2OC3=CC(=O)C=CC3=CC2=C1 FRIPRWYKBIOZJU-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 208000020426 gonococcal urethritis Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 231100001069 micronucleus induction Toxicity 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000005188 oxoalkyl group Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- WVUCPRGADMCTBN-UHFFFAOYSA-M potassium;3-ethoxy-3-oxopropanoate Chemical compound [K+].CCOC(=O)CC([O-])=O WVUCPRGADMCTBN-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940021506 stye Drugs 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- VUMMTQPKHFGQLQ-PKOBYXMFSA-N tert-butyl n-ethyl-n-[1-[(3r)-1-[(1s)-1-phenylethyl]pyrrolidin-3-yl]cyclopropyl]carbamate Chemical compound CC(C)(C)OC(=O)N(CC)C1([C@H]2CN(CC2)[C@@H](C)C=2C=CC=CC=2)CC1 VUMMTQPKHFGQLQ-PKOBYXMFSA-N 0.000 description 1
- GMFKEKQZIAKJBG-FUHWJXTLSA-N tert-butyl n-methyl-n-[1-[(3r)-1-[(1s)-1-phenylethyl]pyrrolidin-3-yl]cyclopropyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)C1([C@@H]2CCN(C2)[C@@H](C)C=2C=CC=CC=2)CC1 GMFKEKQZIAKJBG-FUHWJXTLSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to a synthetic quinoline antibacterial agent useful as a medicament, an animal drug, a marine drug, or an antibacterial preservative.
- quinoline synthetic antibacterial drugs In recent years, the number of low-sensitivity bacteria for quinoline synthetic antibacterial drugs has been increasing in clinical settings. For example, gram-positive bacteria such as Staphylococcus aureus (MRSA) and pneumococcus (PRSP), which are insensitive to lactam antibiotics, and enterococci (VRE), which are insensitive to aminoglycoside antibiotics. Bacteria that have acquired resistance to drugs other than quinolone-based synthetic antibacterials, and that have become less sensitive to quinolone-based synthetic antibacterials, have also emerged and are increasing. Therefore, there is a need for quinolone synthetic antibacterials that are even more effective in clinical settings.
- MRSA Staphylococcus aureus
- PRSP pneumococcus
- VRE enterococci
- quinolone derivatives having a pyrrolidinyl group having an aminomethyl group at the 3-position as a substituent at the 7-position of the quinolone nucleus have strong antibacterial activity against Gram-negative bacteria and Gram-positive bacteria.
- 7- [3- (1-aminomethyl) pyrrolidine-11-yl] quinolonecarboxylic acid derivative [Journal Medicinal Chemistry, Vol. 29, p. 445 (1986)].
- quinolonecarboxylic acid having a substituent on the carbon atom of the aminomethyl group of 3- (1-aminomethyl) pyrrolidine-11-yl group 7- [3- (1-aminomethyl) pyrrolidine-1— Yl] quinolone carboxylic acid derivative [Journal of Medicinal Chemistry, Vol. 36, p. 871 (1993)]; 7 — [3- (1-amino-1-methylethyl) virolidine-11-yl] quinolone carboxylic acid derivative [Journal of Medicinal Chemistry, Vol. 37, p. 733 (1994)]; 7- [3- (1-aminoalkyl) pyrrolidine-11-yl] quinolonecarboxylic acid derivative [Chemical & Pharmaceutical Pretin, Ch. 42, 1442 (1994)].
- a quinolonecarboxylic acid derivative having a 3- (1-aminocycloalkyl) pyrrolidine-11-yl group as a substituent related to the present invention is described as a broad concept in PCT / JP96 / 00208, Here, there are descriptions of compounds represented by the following two structural formulas represented by the following structural formulas A and B.
- the substituent (X 1 ) at the 6-position is defined as a halogen atom or a hydrogen atom.
- the substituent at the 6-position in the quinoline carboxylic acids specifically disclosed in this application is only a halogen atom including a fluorine atom.
- PCT / JP 96/00208 has no specific description of quinolone carboxylic acids in which the 6-position has been replaced by hydrogen.
- this publication discloses 3- (1-aminocycloalkyl) pyrrolidinyl substitution relating to the present invention
- 16-hydrogen-substituted monoquinolonecarboxylic acids as examples.
- X 1 represents a halogen atom or a hydrogen atom
- X 2 represents a halogen atom
- R 2 is
- R 9 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms
- R 1 Q represents hydrogen. It is an alkyl group having 1 to 6 carbon atoms, an alkyl group having 1 to 6 carbon atoms having a hydroxyl group, or an alkyl group having 1 to 6 carbon atoms having a halogen atom.
- the definition of the substituent in the compound represented by the structural formula B is as defined in PCT / JP96 / 002,088. It has nothing to do with the definition of the group.
- a nitrogen-containing heterocyclic substituent for example, a 3- (1-aminoethyl) pyrrolidine-11-yl group, is introduced at the 7-position of the quinolone skeleton via a carbon-nitrogen bond.
- a nitrogen-containing heterocyclic substituent for example, a 3- (1-aminoethyl) pyrrolidine-11-yl group
- a hydrogen-substituted monoquinolone carboxylic acid derivative there is, for example, PCT / W091 / 14214.
- the substituent at the 7-position of the quinolone skeleton shown in Structural Formula C includes 3- (1-aminocycloalkyl) piperidine which is related to the present invention.
- R 1 is a cyclic alkyl group having 3 to 6 carbon atoms, an alkyl group having 1 to 2 carbon atoms, a linear alkenyl group having 2 to 3 carbon atoms, and a branched chain having 3 to 4 carbon atoms Represents an alkyl group or an alkenyl group, wherein the alkyl group or the cyclic alkyl group is unsubstituted, or has 1 to 3 fluorine atoms, unsubstituted or 1 to 3 fluorine atoms on the alkyl group or the cyclic alkyl group.
- R 6 is a hydrogen atom, a hydroxyl group, an aminocarbonyl group, a bromo atom, a cyano group, an alkyl group having 1 to 2 carbon atoms.
- R 6 is a hydrogen atom, a hydroxyl group, an aminocarbonyl group, a bromo atom, a cyano group, an alkyl group having 1 to 2 carbon atoms.
- the ethyl group may be substituted.
- the substituent R 7 is an unsubstituted or one or two amino group which may be substituted with one or two alkyl groups having 1 to 3 carbon atoms, which is bonded to carbon not adjacent to the nitrogen atom of the pyrrolidine ring.
- an aminoalkyl group having an unsubstituted or amino group which may be substituted by an alkyl group having 1 to 3 carbon atoms bonded to the carbon of the pyrrolidine ring wherein the substituent R 9 is a hydrogen atom, a carbon atom Represents a group selected from the group consisting of an alkyl group of 1 to 4, an alkenyl group or alkynyl group of 2 to 6 carbon atoms, and a fuse or spiroalkyl group of 3 to 6 carbon atoms, and the alkyl group portion of these groups is May be unsubstituted or substituted by 1 to 3 fluorine atoms, and the substituents R 7 and R 9 may be substituted to form a pyrrolidine ring and a fused or spiro ring.
- the compound of the present invention can be used in a clinical setting, which cannot be achieved by the compound of the present invention having a substituent having the same structure at the 7-position of the quinoline nucleus, which cannot be achieved. It was also found that it had both excellent safety and good pharmacokinetics. The present invention has been completed based on these findings.
- the 6-hydrogen-substituted monoquinolonecarboxylic acid derivative of the present invention represented by the formula (I), a salt thereof, and a hydrate thereof are compared with a quinolone compound in which the 6-position hydrogen of the compound of the present invention is a fluorine atom.
- the 6-hydrogen-substituted monoquinolone derivative which is the compound of the present invention, is a compound with reduced acute toxicity as compared with the 6-fluorine-substituted monoquinolone derivative, and has a micronucleus inducing effect. It has been found that the compound is a highly attenuated compound with excellent safety and also has good pharmacokinetics, such as an improved urinary recovery rate.
- 3-((aminomethyl) pyrrolidine) which is known to have low selectivity, has a cyclic alkyl group on the methyl group of the pyrrolidine-1-yl group.
- a quinolone compound having a pyrrolidine-11-yl group as a substituent if it is a quinolone compound having the structure of the present invention, it is a compound having excellent selective toxicity, unexpectedly, and The inventor of the present application has found that the compound has excellent pharmacokinetics.
- the present invention relates to a compound represented by the following formula (I), a salt thereof, and It is about these hydrates.
- R 1 represents an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, or a carbon atom having 3 to 6 carbon atoms which may have a substituent.
- 6 cyclic alkyl groups, aryl groups which may have a substituent, heteroaryl groups which may have a substituent, an alkoxy group having 1 to 6 carbon atoms, or an alkylamino group having 1 to 6 carbon atoms Represents
- R 2 and R 1 may be integrated to form a cyclic structure including a part of the mother nucleus,
- the thus formed ⁇ may contain a sulfur atom as a constituent atom of ⁇ , and this ring is further substituted with an alkyl group having 1 to 6 carbon atoms which may have a substituent. Is also good.
- R 3 is a phenylalkyl group composed of an alkylene group having 1 to 6 carbon atoms and a phenyl group, an alkyl group having 1 to 6 carbon atoms, an alkoxymethyl group having 2 to 7 carbon atoms, a hydrogen atom, a phenyl group, and acetyloxymethyl.
- R 4 is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a hydrogen atom, an amino group, a hydroxyl group, a thiol group Or a halogenomethyl group,
- the amino group is substituted with at least one group selected from the group consisting of an alkyl group having 1 to 6 carbon atoms, an acyl group having 2 to 5 carbon atoms, and a formyl group. You may.
- A is a nitrogen atom or formula (II)
- X 1 is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a hydrogen atom, an amino group, Represents a halogen atom, a cyano group, a halogenomethyl group, or a halogenomethoxy group,
- amino group may be substituted with one or more groups selected from the group consisting of alkyl having 1 to 6 carbons, acyl having 2 to 5 carbons and formyl.
- X 1 and the above R 1 may be integrated so as to form a cyclic structure including a part of the mother nucleus, and the ring thus formed may be an oxygen atom, a nitrogen atom or a nitrogen atom.
- An atom or a sulfur atom may be contained as a ring-constituting atom, and this ring may be further substituted with an alkyl group having 1 to 6 carbon atoms which may have a substituent. ) Represents the partial structure represented by.
- R 5 and R 6 each independently represent an alkyl group having 1 to 6 carbon atoms or a hydrogen atom, or a substituted carboxyl group derived from an amino acid, a dipeptide or a triptide;
- the alkyl group may be substituted by one or more groups selected from the group consisting of an alkylthio group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a hydroxyl group, and a halogen atom,
- n an integer 1 or 2.
- the present invention relates to each of the following. That is;
- n in the formula (I) is an integer 1, salts thereof, and waters thereof.
- R 3 in the formula (I) is a hydrogen atom, a salt thereof, and a hydrate thereof;
- R 2 in the formula (I) is a hydrogen atom, salts thereof, and hydrates thereof;
- R 4 in the formula (I) is a hydrogen atom, a salt thereof, and a hydrate thereof;
- a in the formula (I) is a partial structure represented by the formula (II), a salt thereof, and a hydrate thereof;
- X 1 in the formula (II) is a methoxy group, a methyl group, a difluoromethoxy group, a fluorine atom or a chlorine atom, a salt thereof, and a hydrate thereof;
- X 1 in the formula (II) is a methoxy group, a methyl group, a difluoromethoxy group, a fluorine atom or a chlorine atom, a salt thereof, and a hydrate thereof;
- 1 is a methoxy group or a methyl group, a salt thereof, and a hydrate thereof;
- R 5 and R 6 in the formula (I) are a hydrogen atom, a salt thereof, and a hydrate thereof;
- R 5 and R in the formula (I) is a hydrogen atom, and the other is a substituted carboxyl group derived from an amino acid, a dipeptide, or a tripeptide, a salt thereof, and a hydrate thereof. ;
- R 5 and R 6 in the formula (I) are a combination of a hydrogen atom and a methyl group, a salt thereof, and a hydrate thereof;
- R 6 in the formula (I) is a substituted carboxyl group derived from an amino acid, a dipeptide or a tripeptide, a salt thereof, and a hydrate thereof;
- the above compound, wherein the cyclic alkyl group having 3 to 6 carbon atoms which may have a substituent in R 1 is a halogenocyclopropyl group, a salt thereof, and a hydrate thereof;
- the above compound, wherein the halogenocyclopropyl group is a sterically single substituent, a salt thereof, and a hydrate thereof;
- halogenocyclopropyl group is (1R, 2 S) -2-halogenocyclopropyl group, a salt thereof, and a hydrate thereof;
- halogen atom of the halogenocyclopropyl group is a fluorine atom, a salt thereof, and a hydrate thereof;
- a remedy for infectious diseases comprising as an active ingredient any of the above compounds, salts thereof, or hydrates thereof;
- a method for treating a disease comprising administering any of the above compounds, salts thereof, or hydrates thereof as an active ingredient;
- a method for treating infectious diseases comprising administering any of the above compounds, salts thereof, or hydrates thereof as an active ingredient;
- a method for producing a medicament comprising compounding any of the above compounds, salts thereof, or hydrates thereof as an active ingredient;
- a method for producing an antibacterial agent which comprises mixing any of the above compounds, salts thereof, or hydrates thereof as an active ingredient;
- a method for producing a remedy for infectious diseases comprising mixing any of the above compounds, salts thereof, or hydrates thereof as an active ingredient; Use of any of the above compounds, salts thereof, or hydrates thereof for the manufacture of a medicament;
- the substituent R 1 is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, or a C 3 to 6 carbon atom which may have a substituent.
- the alkyl group having 1 to 6 carbon atoms may be a linear or branched alkyl group, more preferably 1 to 4 carbon atoms, and particularly preferably an ethyl group.
- the alkenyl group having 2 to 6 carbon atoms is preferably a vinyl group or a 1-isopropenyl group.
- a 2-fluoroethyl group is preferable.
- the cyclic alkyl group a cyclopropyl group is particularly preferred.
- the cyclic alkyl group may have a substituent, and the substituent is preferably a halogen atom.
- a halogenocyclopropyl group is preferable.
- a fluorine atom is particularly preferred.
- the halogenocyclopropyl group is preferably a monohalogenocyclopropyl group, and more preferably a cis-substituted one.
- Examples of the aryl group which may have a substituent include an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a halogen atom such as a fluorine atom, a chlorine atom and a bromine atom, a hydroxyl group, Examples include a fluorine group which may be substituted by 1 to 3 groups selected from the group consisting of amino group and nitro group (when substituted by a plurality of substituents, a single kind O).
- phenyl, 2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-fluoro-4-hydroxyphenyl, 3-amino-4,6-difluorophenyl and 4 , 6-difluoro-3-methylaminophenyl group is preferred.
- the aryl group means a group derived from an aromatic hydrocarbon compound.
- a naphthyl group can be mentioned, but a tricyclic aryl group of more than this may be used.
- the heteroaryl group is a group derived from a 5- or 6-membered aromatic heterocyclic compound containing at least one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom.
- a 5- or 6-membered nitrogen-containing heterocyclic substituent containing 1 or 2 nitrogen atoms is preferred.
- a pyridyl group, a pyrimidyl group and the like can be mentioned.
- an alkyl group, a halogen atom and the like are preferable.
- a 6-amino-3,5-difluoro-2-pyridyl group is particularly preferred.
- the alkoxy group having 1 to 6 carbon atoms is preferably an alkoxy group derived from the above-mentioned alkyl group, and among them, a methoxy group is preferable.
- the alkylamino group having 1 to 6 carbon atoms the alkyl moiety may be the above-described alkyl group.
- a methylamino group is preferable.
- the substituent R 1 arbitrary preferable cyclic alkyl group or a halogenocyclopropyl group. Of these, a cyclopropyl group or a 2-halogenocyclopropyl group is preferred.
- the halogen atom is preferably a fluorine atom.
- Substituents R z is either alkylthio group or a hydrogen atom from 1 to 6 carbon atoms, or R 1 and and R 2, include a portion of the mother nucleus (i.e., nitrogen atom R 1 is attached and It may be integrated so as to form a cyclic structure composed of polymethylene chains (to include the carbon atom to which R 2 is bonded).
- the thus formed ⁇ may include a sulfur atom as a constituent atom of the ring, and the ring may have an alkyl group having 1 to 6 carbon atoms or a halogenoalkyl group as a substituent.
- the ring formed may be of the size of a 4- to 6-membered ring, and this ring may be saturated or unsaturated.
- the substituent R 7 represents an alkyl group having 1 to 6 carbon atoms such as a methyl group, a halogenoalkyl group having 1 to 6 carbon atoms such as a fluoromethyl group, or a hydrogen atom
- the substituent R 8 represents Represents a halogen atom such as a fluorine atom or a hydrogen atom.
- the substituent R 2 of the compound of the formula (I) is preferably a hydrogen atom.
- the substituent R 3 is composed of an alkylene group having 1 to 6 carbon atoms and a phenyl group Phenylalkyl group (aralkyl group), alkyl group having 1 to 6 carbon atoms, alkoxymethyl group having 2 to 7 carbon atoms, hydrogen atom, phenyl group, acetomethyl group, pivaloyloxymethyl group, ethoxycarbonyl group, choline A dimethylaminoethyl group, a 5-indanyl group, a phthalidinyl group, a 5-alkyl-2-oxo-1,3-dioxol-4-ylmethyl group, or a 3-acetoxy-12-oxobutyl group.
- R 4 is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a hydrogen atom, an amino group, a hydroxyl group, and a thiol group. Or a halogenomethyl group, wherein the amino group is substituted with at least one group selected from the group consisting of an alkyl group having 1 to 6 carbon atoms, an acyl group having 2 to 5 carbon atoms, and a formyl group. It may be. When substituted by a plurality of groups, they may be all the same, or may be a plurality of different types.
- the alkyl group may be linear or branched having 1 to 6 carbon atoms, and is preferably a methyl group, an ethyl group, a normal propyl group, or an isopropyl group.
- the alkenyl group may be a straight or branched one having 2 to 6 carbon atoms, but is preferably a vinyl group.
- the alkynyl group may be a linear or branched one having 2 to 6 carbon atoms, and is preferably an ethynyl group.
- the halogen in the halogenomethyl group is particularly preferably a fluorine atom, and the number thereof may be 1 to 3.
- the alkoxy group may have 1 to 6 carbon atoms, but is preferably a methoxy group.
- the substituent R 4 is preferably a hydrogen atom, an alkyl group, or an amino group, and among them, a hydrogen atom, a methyl group, or an unsubstituted amino group (—NH 2 ) is particularly preferable.
- a hydrogen atom, a methyl group, or an unsubstituted amino group (—NH 2 ) is particularly preferable.
- the substituent R 4 is an amino group, a hydroxyl group, or a thiol group, these may be protected by a protecting group usually used in this field.
- protecting groups include (substituted) alkoxycarbonyl groups such as tertiary butoxycarbonyl group and 2,2,2-trichloroethoxycarbonyl group; benzyloxycarbonyl group, paramethoxybenzyloxy group (Substituted) aralkyloxycarbonyl groups such as carbonyl group and paranitrobenzyloxycarbonyl group; acetyl group, methoxyacetyl group, trifluoroacetyl group, chloroacetyl group, bivaloyl group, formyl group, (Substituted) acyl groups such as benzoyl group; (substituted) alkyl groups such as tertiary butyl group, benzyl group, paranitrobenzyl group, paramethoxybenzyl group, triphenylmethyl group, or (substituted) aralkyl groups A methoxymethyl group, a tert-butoxymethyl group, a
- (Alkyl and / or aralkyl) substituted silyl groups are (Here, “(substituted)” means that the compound may have a substituent.)
- a compound having an amino group, a hydroxyl group, or a thiol group protected by these substituents is Particularly, it is preferable as an intermediate during production.
- A is a nitrogen atom or formula (II) Is any of the partial structures represented by
- X 1 is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, and an alkyl group having 1 to 6 carbon atoms.
- An alkoxy group represents a hydrogen atom, an amino group, a halogen atom, a cyano group, a halogenomethyl group, or a halogenomethoxy group, of which an amino group is an alkyl group having 1 to 6 carbon atoms and an acyl group having 2 to 5 carbon atoms. Substituted by one or more groups selected from the group consisting of It may be.
- the alkyl group may be a linear or branched alkyl group having 1 to 6 carbon atoms, and is preferably a methyl group, an ethyl group, a normal propyl group or an isopropyl group.
- the alkenyl group may be linear or branched having 2 to 6 carbon atoms, and is preferably a vinyl group.
- the alkynyl group may be linear or branched having 2 to 6 carbon atoms, and is preferably an ethynyl group.
- the halogen of the halogenomethyl group is particularly preferably a fluorine atom, and the number thereof may be 1 to 3.
- the alkoxy group may have 1 to 6 carbon atoms, but is preferably a methoxy group.
- the halogen of the halogenomethoxy group is particularly preferably a fluorine atom, and the number thereof may be 1 to 3.
- an alkyl group or an alkoxy group is preferable. More preferred are a methyl group, an ethyl group, a methoxy group, and a difluoromethoxy group.
- this X 1 and R 1 described above form a cyclic structure comprising a polymethylene chain including a part of the mother nucleus (including the carbon atom to which X 1 is bonded and the nitrogen atom to which is bonded).
- the ring thus formed may contain an oxygen atom, a nitrogen atom, or a sulfur atom as a constituent atom of the ring, and the ring has a substituent.
- An alkyl group having 1 to 6 carbon atoms which may be substituted.
- the ⁇ formed here may have a size of a 5- to 7-membered ring, and the constituent atoms of the ring are not limited to carbon atoms but include an oxygen atom, a nitrogen atom, or a sulfur atom. You may go out. Further, ⁇ formed may be saturated or unsaturated.
- the ring formed here may have an alkyl group having 1 to 6 carbon atoms as a substituent. This alkyl group may be considered in the same manner as the above-mentioned alkyl group, but is preferably a methyl group. This alkyl group may be substituted by a halogen atom, an alkoxy group, or the like.
- A is a partial structure of the formula (II):
- Preferred as a combination of R 4 and X 1 is an alkyl group having 1 to 6 carbon atoms, an amino group, a hydrogen atom, or a hydroxyl group.
- X 1 is an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a halogenomethoxy group, or a hydrogen atom.
- a more preferable combination is an amino group, a hydrogen atom, a hydroxyl group, or a methyl group, and X 1 is a methyl group, a methoxy group, a difluoromethoxy group, or a hydrogen atom.
- R4 is a hydrogen atom, a hydroxyl group or a methyl group, is where X 1 is a methyl group or a methoxy group.
- the substituents R 5 and R 6 each independently represent an alkyl group having 1 to 6 carbon atoms or a hydrogen atom, or a substituted carboxyl group derived from an amino acid, a dipeptide or a tripeptide.
- This alkyl group may be substituted by one or more groups selected from the group consisting of an alkylthio group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a hydroxyl group and a halogen atom.
- the alkyl group may be linear or branched having 1 to 6 carbon atoms, and is preferably a methyl group, an ethyl group, a normal propyl group, and an isopropyl group.
- the alkyl group has a carbon number of 1 to 6 may be either linear or branched, and more preferably, the hydroxyl group is substituted on the terminal carbon atom of the alkyl group.
- the alkyl group having a hydroxyl group preferably has up to 3 carbon atoms, and is preferably a hydroxymethyl group, a 2-hydroxyethyl group, a 2-hydroxypropyl group, a 3-hydroxypropyl group, or the like.
- the alkyl group may be linear or branched having 1 to 6 carbon atoms, and the halogen atom is preferably a fluorine atom. Further, the number of fluorine atoms may be any one from mono substitution to perfluoro substitution. Examples thereof include a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, and a 2,2,2-trifluoroethyl group.
- the alkyl group may be linear or branched having 1 to 6 carbon atoms, and the alkylthio group may be linear or branched having 1 to 6 carbon atoms. Either may be used.
- the alkyl group having an alkylthio group is preferably an alkylthiomethyl group, an alkylthioethyl group or an alkylthiopropyl group, and more preferably an alkylthio group having 1 to 3 carbon atoms. More preferred examples include a methylthiomethyl group, an ethylthiomethyl group, and a methylthioethyl group.
- the alkyl group When the alkyl group has an alkoxy group as a substituent, the alkyl group may be linear or branched having 1 to 6 carbon atoms, and the alkoxy group may be linear or branched having 1 to 6 carbon atoms. Either may be used.
- the alkyl group having an alkoxy group an alkoxymethyl group, an alkoxyethyl group, and an alkoxypropyl group are preferable, and further, the alkoxy group preferably has up to 3 carbon atoms. More preferred are a methoxymethyl group, an ethoxymethyl group and a methoxyethyl group.
- R 6 one is a hydrogen atom, the other is a hydrogen atom, an alkyl group or an amino acid, a dipeptide, or if a substituted carboxyl group of the tripeptide - derived are preferred. More preferably, one of R 5 and R 6 is a hydrogen atom, and the other is a hydrogen atom or an alkyl group. As the alkyl group, a methyl group or an ethyl group is preferred. And a methyl group is particularly preferred. Accordingly, it is particularly preferred that: R 5 and R 6 are both hydrogen atoms, or a combination in which one is a hydrogen atom and the other is a methyl group. In particular, the compounds of this combination can exhibit a preferred physiological activity as an antibacterial agent.
- a quinoopene derivative in which one of the substituents R 5 and R 6 is a hydrogen atom and the other is a substituted carboxyl group derived from an amino acid, a dipeptide or a triptide is particularly useful as a prodrug It is. A specific example of this will be described later.
- halogen atom to be substituted examples include a fluorine atom and a chlorine atom, and a fluorine atom is particularly preferable.
- the halogen atom and the quinoline carboxylic acid moiety have a cis configuration with respect to the cyclopropane ring.
- substituents in the cis configuration include 2- (S) -halogeno 1- (R) -cyclopropyl group and 2- (R) -halogeno 1- (S) -cyclopropyl group. Of these, The former is preferred.
- the compound of the present invention is a quinolone mother nucleus, in particular, having a 2- (S) -halogeno-1- (R) -cyclopropyl group, and having a [2- (S) -fluoro-11 (R) -cyclopropyl] group.
- -1,4-dihydro-14-oxoquinoline-13-capillic acid has excellent characteristics by having a substituent of the structure shown in Structural Formula E at the 7-position of the sulfonic acid skeleton.
- more preferred compounds have the following structures. That is, a 3- (1-aminocycloalkyl) pyrrolidine derivative-substituted 16-hydrogen-substituted quinolonecarboxylic acid, a salt thereof, and a hydrate thereof represented by the formula (I) are preferably (particularly the 3-position of the pyrrolidine ring described above) And its salts, and their hydrates) have a wide range of potent antibacterial activity against Gram-negative and Gram-positive bacteria, especially those containing MRSA, PRSP and VRE. It is a feature of the compound of the present invention that it exhibits strong antibacterial activity against resistant bacteria represented by positive cocci.
- n in the substituent is an integer of 1 or 2, and particularly in a compound in which n is an integer of 1. Is recognized. That is, a compound in which the cyclic portion is a three-membered ring is a preferred compound.
- the compound of the formula (I), which is the compound of the present invention has a diastereomeric structure
- This “consisting of a single diastereomer” is understood to include not only the case where no other diastereomer is contained, but also the case where it is chemically pure. In other words, other diastereomers may be included as long as they have no effect on physical constants or physiological activities.
- stereochemically single includes asymmetric carbon atoms in compounds, etc. Therefore, when there are multiple types of isomers that are in an isomer relationship, it means that they are composed of only one of them. In this case as well, this “unity” is considered in the same manner as above.
- the quinolone carboxylic acid derivative of the present invention may be in a free form, but may be in the form of an acid addition salt or a salt of a carboxyl group.
- acid addition salts include inorganic salts such as hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide and phosphate; or methane sulfonate, benzene sulfone Organic acid salts such as acid salt, toluene sulfonate (sulfonate); acetate, citrate, maleate, fumarate, lactate (carboxylate); and the like.
- Examples of the salt of the carboxyl group include lithium metal salts such as lithium salts, sodium salts and potassium salts; alkaline earth metal salts such as magnesium salts and calcium salts; ammonium salts; and triethylamine. Salt, N-methylglucamine salt, tris (hydroxymethyl) aminomethane salt; and the like, and any of inorganic salts and organic salts may be used.
- the quinoline carboxylic acid derivative free form, acid addition salt, and carboxyl group salt may exist as a hydrate.
- a carboxylic acid compound in which the substituent R 3 is a hydrogen atom it is preferable to use a carboxylic acid compound in which the substituent R 3 is a hydrogen atom, while a quinolone derivative in which the carboxylic acid moiety is an ester is a synthetic intermediate or Useful as a prodrug.
- alkyl esters, benzyl esters, alkoxyalkyl esters, phenylalkyl esters, and phenyl esters are useful as synthetic intermediates.
- Esters used as prodrugs are esters that are easily cleaved in vivo to form a free form of carboxylic acid, and include, for example, acetomethoxymethyl ester, bivaloyloxymethyl ester, and ethoxycarbonyl ester.
- acetomethoxymethyl ester bivaloyloxymethyl ester
- ethoxycarbonyl ester ethoxycarbonyl ester.
- choline ester dimethylaminoethyl ester, 5-indanyl ester and phthalidinyl ester, 5-alkyl-l-oxo-l, 3-dioxo-l-l-l-l-methyl and 3-acetoxy-l- Oxobutyl esthetic And oxoalkyl esters such as
- quinolone derivatives in which one of the substituents H 5 and R 6 is a hydrogen atom and the other is a substituted carboxyl group derived from an amino acid, a dipeptide or a triptide are useful as prodrugs .
- Amino acids, dipeptides, and tripeptides used to obtain such prodrugs have a peptide bond formed from the carboxyl group and the amino group present at the substituent at the 7-position of the quinolone carboxylic acid derivative. It is easily cleaved in the body to produce a free form of amine, for example, amino acids such as glycine, alanine, and aspartic acid; dipeptides such as glycine-glycine, glycine-alanine, and alanine-alanan; and Examples include substituted carbonyl groups derived from tripeptides such as glycine-glycine-alanine and glycine-alanine-alanine.
- the compound of the present invention represented by the formula (I) can be produced by various methods.
- One preferable example is, for example, a compound represented by the formula (III)
- X 2 is a substituted or unsubstituted phenylsulfonyl group, having a carbon number of 1 to
- 3 represents a substituent that functions as a leaving group, such as a substituted or unsubstituted alkylsulfonyl group, a fluorine atom, a chlorine atom, or a bromine atom;
- R 3 1 is R 3 in defined in formula (I), or Formula (IV)
- Upsilon 3 2 and Upsilon 3 3 are the same or different, represent a fluorine atom or an alkyl carbonylation Ruokishi group having 2 to 4 carbon atoms.
- RR 2 , R 4 , R 5 , R 6 , and A are the same as defined in formula (I). ]
- R 5 1 and R B 1 are each independently a hydrogen atom, a protecting group of the alkyl group or Amino groups, from 1 to 6 carbon atoms, further, both of the R 5 1 and R 6 1 One represents a hydrogen atom and the other represents an unsubstituted or substituted carboxyl group derived from an amino acid, dipeptide, or tripeptide having an amino group protected by an amino-protecting group,
- the alkyl group may have, as a substituent, a group selected from the group consisting of an alkylthio group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a hydroxyl group, and a halogen atom.
- n is the same as defined in the formula (I). ]
- reaction is carried out in the presence of a reagent that converts the salt into a free form).
- acid addition salts include inorganic salts such as hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide, and phosphate; or methanesulfonate, benzenesulfonate, Organic acid salts such as toluenesulfonate (sulfonates); acetate, citrate, maleate, fumarate, and lactate (carboxylates);
- the reaction can be carried out with or without a solvent.
- the solvent used in the reaction may be any solvent that does not adversely affect the reaction, such as dimethyl sulfoxide, pyridine, acetonitrile, ethanol, chloroform, and dimethyl methyl. Examples include formamide, dimethylacetamide, N-methylpyrrolidone, tetrahydrofuran, water, 3-methoxybutanol, or mixtures thereof.
- the reaction may be an acid acceptor, such as an inorganic or organic base, for example, an inorganic basic compound such as an alkali metal or alkaline earth metal carbonate or bicarbonate, or triethylamine, pyridine, 1,8-diamine. It is preferable to carry out the reaction in the presence of an organic basic compound such as azabicycloundecene, N-methylpiperidine, N, N-diisoprovirethylamine.
- an organic basic compound such as azabicycloundecene, N-methylpiperidine, N, N-diisoprovirethylamine.
- the reaction temperature may be in the range of room temperature to 200 ° C., preferably in the range of 25 to 150 ° C.
- the reaction time may be in the range of 30 minutes to 48 hours, and is usually completed in about 30 minutes to 8 hours.
- the protecting group for the amino group may be any protecting group commonly used in this field, and includes, for example, a substituent such as a tertiary butoxycarbonyl group and a 2,2,2-trichloromouth ethoxycarbonyl group.
- a substituent such as a tertiary butoxycarbonyl group and a 2,2,2-trichloromouth ethoxycarbonyl group.
- Ethers which may be substituted; substituted silyl groups such as trimethylsilyl group, isopropyldimethylsilyl group, tertiary butyldimethylsilyl group, tribenzylsilyl group and tertiary butyldiphenylsilyl group; .
- R 3 and R 31 each comprise an alkyl group having 1 to 6 carbon atoms, an alkoxymethyl group having 2 to 7 carbon atoms, or an alkylene group having 1 to 6 carbon atoms and a phenyl group
- a phenylalkyl group (aralkyl group)
- it can be converted to a carboxylic acid by treating it under acidic or basic conditions generally used for hydrolysis of a carboxylic acid ester.
- R 31 has the structure of the formula (IV)
- the compound (V) is reacted with the compound (III) and then converted into a carboxylic acid by hydrolysis under acidic or basic conditions.
- the desired compound of the formula (I) can be obtained by removing the protecting group under appropriate conditions corresponding to the protecting group.
- the compound of the formula (V) can be produced by various methods.
- the compound of formula (V) has the following formula
- R 5 12 is as defined in formula (I): is the same as R 5 or represents a protecting group for an amino group, and n is the same as defined in formula (I) It is. Q is a protecting group for an amino group.
- the protecting group for the amino group is selected from the group consisting of (substituted) alkoxycarbonyl group, (substituted) aralkyloxycarbonyl group, (substituted) acryl group, (substituted) alkyl group, (substituted) aralkyl group, and substituted silyl group. It can be chosen. ]
- the above compounds may also exist as salts, hydrates, or hydrates of the salts.
- acid addition salts include inorganic and organic acid salts. Examples of these are inorganic salts such as hydrochloride, sulfate, hydrobromide, hydroiodide and phosphate; or methanesulfonate, benzenesulfonate, and toluenesulfonate ( Sulfonates); acetate, citrate, maleate, fumaric acid And organic acid salts such as salts and lactates (carboxylates).
- R 5 1 2 and Q is a protective group of either Amino groups, they may also be different from one in the same, it is of compounds are those, each of which is cut by the different reaction conditions (I ) Is advantageous.
- the R 5 1 2 and Q is a protecting group of the Amino group
- Ru can be mentioned the following. That is, (substituted) alkoxycarbonyl groups, (substituted) aralkyloxycarbonyl groups, (substituted) acyl groups, (substituted) alkyl groups, (substituted) aralkyl groups, and (substituted) silyl groups.
- alkoxycarbonyl groups such as tertiary butoxycarbonyl group, 2,2,2-trichloroethoxycarbonyl group, etc .
- benzyloxycarbonyl group, paramethoxybenzyloxycarbonyl group (Substituted) aralkyloxycarbonyl groups such as nitropentyloxycarbonyl group; such as acetyl group, methoxyacetyl group, trifluoroacetyl group, chloroacetyl group, bivaloyl group, formyl group, and benzoyl group; Substitution) acyl groups; tertiary butyl group, benzyl group, paranitrobenzyl group, paramethoxybenzyl group, triphenylmethyl group, etc.
- the compound (I) When producing the compound (I) using the above compound having a protecting group Q, it is necessary to react after removing the protecting group Q. In this case, immediately after the removal of the protecting group, the compound (V) may be reacted with the compound (III) or (V) by a so-called one-port reaction. The reaction may be performed after isolation.
- the compound of the formula (VI) can be produced by various methods in the same manner as the compound of the formula (V).
- One example is the method described in PCT / JP96 / 002.08. Yes, but not limited to.
- the cis-2-fluorocyclopropylamine consisting of a single isomer which is preferable for the synthesis of the compound of the formula (I) consisting of a single isomer, can be obtained, for example, by the method described in JP-A-2-213475. Can be synthesized.
- the synthesis of the compound of the formula (I) consisting of a single isomer from the optically active cis-1-fluorocyclopropylamine derivative thus obtained is described in, for example, JP-A-2-231475. It can be implemented by the method described in the item.
- the compound of the present invention Since the compound of the present invention has a strong antibacterial activity, it can be used as a medicament for humans, animals, and fish, or as a preservative for agricultural chemicals and foods.
- the dose may be in the range of 5 Omg to 1 g per adult, preferably in the range of 10 Omg to 50 Omg. is there.
- the dosage for animals will vary depending on the purpose of the administration (treatment or prevention, etc.), the type and size of the animal to be treated, the type and extent of the infected pathogen, but generally the daily dose is It may be in the range of lmg to 20Omg per kg of body weight, preferably in the range of 5mg to 10Omg.
- This daily dose may be administered once a day or in 2 to 4 divided doses.
- the daily amount may exceed the above amount if necessary.
- the compounds of the present invention are active against a wide range of microorganisms that cause various infectious diseases and can treat, prevent or reduce the diseases caused by these pathogens.
- Pacteria or Pacteria-like microorganisms for which the compound of the present invention is effective include Pudu, Streptococcus pyogenes, Hemolytic streptococci, Enterococci, Pneumococci, Peptostreptococcus, Neisseria gonorrhoeae, Escherichia coli, Citricopagus, Shigella, Pneumonia Bacillus, Enterobacter, Serratia, Proteus, Pseudomonas aeruginosa, Haemophilus influenzae, Acinetobacter genus, Campylobacter genus, Trachoma chlamydia and the like can be exemplified.
- Diseases caused by these pathogens include folliculitis, sickness, sickness, erysipelas, cellulitis, lymphatic (node) inflammation, glanders, subcutaneous abscess, hidritis, collective acne, infectious dust, Perianal abscess, mastitis, trauma, burns, superficial secondary infections such as surgical wounds, pharyngolaryngitis, acute bronchitis, tonsillitis, chronic bronchitis, bronchiectasis, diffuse panbronchiolitis, Secondary infection of chronic respiratory disease, pneumonia, pyelonephritis, cystitis, prostatitis, epididymitis, gonococcal urethritis, nongonococcal urethritis, cholecystitis, cholangitis, bacillary dysentery, enteritis, uterine appendixitis , Intrauterine infection, Bartholin's adenitis, blepharitis, stye,
- tuberculosis bacteria mycobacterium (hereinafter abbreviated as M.) tuberculosis, M. bobius, M. africanum] and atypical acid-fast bacteria [M. kansasii] , M. Marainam, M. Scrophase, M. Abium, M. intracellulare, M. xenobi, M. fortiyutum, M. Ceronnay].
- Mycobacterial infections caused by these pathogens can be broadly classified into three categories: tuberculosis, atypical mycobacteriosis, and leprosy.
- Mycobacterium tuberculosis infection in addition to lungs, thoracic cavity, trachea ⁇ bronchi, lymph nodes, systemic dissemination, osteoarthritis, meninges ⁇ brain, digestive system (intestines ⁇ liver), skin, mammary gland, eyes, middle ear ⁇ pharynx , Urinary tract, male genitals, female genitals, etc.
- the main organ affected by atypical mycobacteriosis is the lung, and other examples include local lymphadenitis, skin and soft tissue, osteoarthritis, and systemic dissemination. be able to.
- Illustrative disease names are, for example, Escherichia coli, chick dysentery, chicken paratyphoid, poultry cholera, infectious coryza, podococcosis, mycoplasma infection, etc. in birds, and Escherichia coli, salmonellosis, pasteurella disease, hemophilus infection in pigs. Disease, atrophic rhinitis, exudative epidermitis, mycoplasma infection, etc., Escherichia coli, salmonellosis, hemorrhagic sepsis, mycoplasma infection in cattle, E. coli sepsis, salmonella infection in dogs, bovine lung disease, mastitis, etc. And cats such as exudative pleurisy, cystitis, chronic rhinitis, hemophilus infection, diarrhea of kittens, mycoplasma infection and the like.
- the antibacterial preparation comprising the compound of the present invention can be prepared by selecting an appropriate preparation according to the administration method and preparing various commonly used preparations.
- Examples of the dosage form of the antibacterial preparation containing the compound of the present invention as a main component include tablets, powders, granules, capsules, solutions, syrups, elixirs, oily or aqueous suspensions, and the like.
- Injectables include stabilizers, preservatives, and solubilizing agents in the preparation.
- a solution containing these adjuvants When a solution containing these adjuvants is contained in a container, it is used as a solid preparation by freeze-drying or the like. It may be prepared as a preparation.
- One dose may be stored in a container. Alternatively, multiple doses may be stored in the same container.
- Examples of the external preparation include solutions, suspensions, emulsions, ointments, gels, creams, lotions, and sprays.
- Solid dosage forms may contain pharmaceutically acceptable additives together with the active compound, such as fillers, extenders, binders, disintegrants, dissolution enhancers, wetting agents, Lubricants and the like can be selected and mixed as needed to form a formulation.
- Liquid preparations include solutions, suspensions, emulsions and the like, and may also contain suspending agents, emulsifiers and the like as additives.
- a method of administering the compound of the present invention to an animal a method of orally administering it directly or by mixing it in a feed, a method of orally administering a solution, and then directly or adding it to drinking water or a feed
- a method for administering the compound of the present invention to an animal include a powder, a fine granule, a soluble powder and the like, which are appropriately prepared by a technique generally used in this field. It can be a powder, syrup, solution, or injection.
- 2,4-Difluoro-3-methylbenzoic acid (4.97 g, 28.9 mmo 1) was dissolved in toluene (50 ml), and N, N-dimethylformamide (0.1 ml), thionyl chloride (3.16 ml, After adding 43.4 mmo 1), the mixture was stirred in an oil bath at 80 ° C for 14 hours. After allowing the reaction mixture to cool, it was concentrated under reduced pressure. Toluene was added to the residue, and concentration under reduced pressure was repeated, and the obtained residue was dissolved in tetrahydrofuran (10 ml).
- Example 1 7- “3- (R)-(1-aminocyclopropyl) pyrrolidine-1- 1-yl 1—1—“ 2- (S) —fluoro-1- (R) —cyclopropyl ⁇ -1. 4 Jihi-d'oh 8-Methyl-4-oxoquinoline 3-Carbon
- IR (KBr, disk): 3375, 3062, 3006, 2925, 286 4, 1728, 16 10, 1508, 1475, 1431, 1394, 1348, 1315, 1257 cm " 1 .
- the obtained yellow oil was dissolved in 1,4-dioxane (600 ml), and 60% oily sodium hydride (5.94 g, 242 mmo 1) was gradually added under cooling with water. After stirring the reaction mixture at room temperature for 30 minutes, the reaction solution was concentrated under reduced pressure to about 300 ml. The resulting concentrate was slowly poured into 1 mo 1/1 hydrochloric acid stirred under water cooling, and the precipitated crystals were collected by filtration. After washing the crystals in the order of excess purified water, a small amount of ethanol, and excess getyl ether, the resulting crude crystals were converted to a slurry with ethyl acetate and purified to give 49.4 g of the title compound as colorless crystals (80. 9%).
- the collected crystals are washed with excess water, washed with cold ethanol and then with ethyl acetate, dried under reduced pressure, and the resulting crude crystals are purified by recrystallization from a mixed solvent of acetonitrile-ethanol and dried under reduced pressure to obtain a white powder.
- the title compound was obtained in the form of 27.1 g (87.4%).
- Example 2 7— “3_ (R) -I- (1-aminocyclopropyl) pyrrolidine-111-yl” -1-1 ”2 -— (S-Fluoro-1-1 (R) -cyclopropyl-—1.4 Dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid
- Example 3 7- "3- (R)-(1-aminocyclopropyl) pyrrolidine-l-yl-l-l-cyclopropyl-l.4-dihydro-l-8-methyl-14-oxoquinoline-l 3- Power rubonic acid
- Monoethyl malonate (6.61 g, 50. Ommo 1) was dissolved in anhydrous tetrahydrofuran (10 Oml), and magnesium ethoxide (3.15 g, 28. Ommo 1) was added under ice-cooling. The mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure to prepare a monoethyl malonate magnesium salt. Then, 2, 6 — Dissolve nicotinic acid (3.84 g, 20. Ommo 1) in anhydrous tetrahydrofuran (80 ml) and add 1,1-carbonyldiimidazole (4.87 g, 30. Ommo 1) under ice-cooling.
- Ethyl 2- (2,6-dichrolic nicotinol) acetate (7.03 g, 26.8 mmol) was dissolved in acetic anhydride (30 ml), and triethyl orthoformate (6 Oml) was added. Stirred in oil bath at ° C. After allowing the reaction solution to cool, toluene (50 ml) was added to the residue obtained by concentration under reduced pressure, and the mixture was concentrated under reduced pressure. This operation was repeated three times, and the obtained residue was dried under reduced pressure to obtain 8.42 g of ethyl 2- (2,6-dichloronicotinol) _3-ethoxyacrylate as a yellow oil.
- Example 4 7- "3_ (R)-(1-aminocyclopropyl) pyrrolidine-1.1-yl, -1-1" 2- (S) -fluoro-1-1 (R) -cyclopropyl-1-1. 4 Dihydro-4-oxo-1, 8-10-Futyridine-1 3-Carbonic acid
- the precipitated crystals were collected by filtration, washed with excess water, a small amount of cold ethanol and excess getyl ether, and dried under reduced pressure at 80 ° C for 16 hours to give the title compound 3.51 g (95%) Was obtained as a white powder.
- Example 6 7- "3- (R)-( ⁇ -aminocyclopropyl) pyrrolidine-1- (1-yl) -1-cyclopropyl-18-difluoromethoxy-1-!. 4-dihydro-4-oxoquinoline-3-carboxylic acid
- the obtained residue was purified by recrystallization from a mixed solvent of 2-propanol / chloroform / 28% aqueous ammonia, and dried under reduced pressure to give the title compound (7.07 g, 71%) as a yellow powder. .
- Example 7 5-amino-1 7- "3- (R)-(1-aminocyclopropyl) pyrrolidine-1-yl, 1-" 2-(?-Fluoro-1--cyclocyclopropyl) ⁇ —1.4-Dihydro-8-methyl-14-oxoquinoline-13-carboxylic acid 3- (R)-[1- [N- (tert-butoxycarbonyl) amino] cyclopropyl] pyrrolidine (643 mg, 2.55 mmo l) Triethylamine (0.5 ml) was added to dry dimethylsulfoxide (1 ml), and then 5-amino-17-fluoro-1_ [2- (S) -fluoro-11- (R) -cyclopropyl] -11 , 4-Dihydro-1-8-methyl-1-oxoquinoline_3-carboxylic acid (25 Omg, 85 Ojmol) was added, and the mixture was stirred at 70 ° C.
- Ethyl 6,7-difluoro-11- [2- (S) monofluoro-11 (R) -cyclopropyl] _1,4-dihydro-18-methoxy-5-nitro-1-4-oxoquinone-13-carboxylate ( 13.96 g, 36.14 mmo 1) was dissolved in dimethylformamide (180 ml), and 28% aqueous ammonia (60 ml) was added dropwise under ice-cooled stirring. After the reaction solution was stirred at room temperature for 64 hours, water (100 ml) was added to the reaction solution, followed by concentration under reduced pressure.
- Example 8 5-amino-1 7- "3- (R)-(1-aminocyclopropyl) pyrrolidine-1-yl- 1- ⁇ 2- (S) -fluoro-1 ((-cyclopropyl ⁇ _1. 4-dihydro-8-methoxy 4-oxoquinoline 3-butane
- the basic aqueous solution was adjusted to pH 7.8 with 1 mo 1/1 hydrochloric acid, and then extracted with black form (10 Oml X 3). After the combined organic layers were dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The obtained residue was purified by recrystallization from a mixed solvent of ethanol and lugetyl ether, and dried under reduced pressure to obtain 74 mg (9%) of the title compound as yellow crystals.
- Example 9 10— “3— (R) — (1-aminocyclopropyl) pyrrolidine-1-yl 1-2.3.3-dihydro-1-S) —tyl-7-oxo-17H-pyrido
- the organic layer was washed with a 10% aqueous solution of citric acid (50 ml) and a saturated saline solution (50 ml), and the organic layer was dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, concentrated hydrochloric acid (6 ml) was added dropwise to the residue under ice, and the mixture was stirred at room temperature for 30 minutes. 4 ml of water was added to the reaction solution, and the acidic aqueous solution was washed with chloroform (10 ml ⁇ 3), and adjusted to pH 12.0 with an aqueous sodium hydroxide solution.
- Example 11 1 1- "2- (S) -Fluoro-11- (R) -cyclopropyl 1-8-methoxy-7-" 3- (R- "1- (methylamino) cyclopropyl-pyrrolidine-1 1 1 ⁇ T 1 1 1, 4-dihydro-4-oxoquinoline 13-carboxylic acid 3- (R) — [1— [N— (tert-butoxycarbonyl) 1 N— (methyl) amino] cyclopropyl] Pyrrolidine (102 mg, 379 umo 1) s triethylamine (0.50 ml) was added to dry dimethyl sulfoxide (1 ml), and then 7-fluoro-1- (2- (S) -fluoro-1- (R) -cyclopropyl ] 1,4-Dihydro-8-methoxy-14-oxoquinoline-13-carboxylic acid (112 mg, 379 / mo 1) was added, and the mixture was heated and stirred in a 100
- reaction mixture was concentrated under reduced pressure, and the residue was dissolved in chloroform (100 ml). After washing with l), the organic layer was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, concentrated hydrochloric acid (2 ml) was added dropwise to the residue under ice-cooling, and the mixture was stirred at room temperature. To the reaction solution was added lmol / 1 hydrochloric acid (2 ml), the yellow acidic aqueous solution was washed with chloroform (50 ml ⁇ 4), and the pH was adjusted to 12.0 with aqueous sodium hydroxide solution.
- the basic aqueous solution was adjusted to pH 7.4 with lmo 1/1 hydrochloric acid, extracted with chloroform (100 ml ⁇ 3), dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- Example 12 5-Amino “2-—Fluoro-11-Cirrobutyl pill —8-Methyl-17—” 3— (R-1 “1- (Methylamino) cyclopropyl ⁇ pyrrolidine-1-yl ⁇ —1. 4 dihydro-4 _ oxoquinoline one 3-carvone
- Example 13 ? .. 3-dihydro-1- 3--chill-10-"3- (R) -11- (methylamino) cyclopropyl ⁇ pyrrolidine-11-yl ⁇ _7-oxo-17H-pyrid" 1.2.3 — D el “1.4 ⁇ Ben, Xazazine- 1-6-Carbonic acid 3- (R)-[1— [N— (Tertiary butoxycarbonyl) — N— (Methyl) ami [No] cyclopropyl] pyrrolidine (125 mg, 521 zmol) and triethylamine (0.50 ml) were added to dry dimethyl sulfoxide (1 ml), and then 10 monofluoro-2,3-dihydro-3- (S) -methyl-7 —Oxo 7H—Bide [1,2,3-de] [1,4] benzoxazine-16-carboxylic acid (132 mg, 500 zmo 1), and in a nitrogen
- Example 15 1- (cyclopropyl) -18-methyl-7- "3- (R) mono- (methylamino) cyclopropyl ⁇ pyrrolidine-1-yl ⁇ -1.4-dihydro-14-oxoquinoline-l-3-hydroxylbon Acid
- the organic layer was washed with a 10% aqueous solution of citric acid (100 ml), and the organic layer was dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, concentrated hydrochloric acid (6 ml) was added dropwise to the residue under ice cooling, and the mixture was stirred at room temperature for 30 minutes. To the reaction mixture was added lmo-1-hydrochloric acid (12 ml), the yellow acidic aqueous solution was washed with chloroform (50 ml ⁇ 3), and the pH was adjusted to 12.0 with an aqueous sodium hydroxide solution.
- the concentrate was extracted with ethyl acetate (750 ml ⁇ 2), washed with a 10% aqueous sodium thiosulfate solution (500 ml ⁇ 2) and a saturated aqueous sodium bicarbonate solution (500 ml 2) in that order, and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to give the title compound (291 g, 97%) as a yellow oil.
- Ethyl Getyl phosphonoacetate (100 g, 446 mmo 1) is dissolved in ethanol (275 ml), and 2 mol of 1/1 sodium hydroxide aqueous solution is added under ice-cooling and stirring. After the liquid (275 ml, 55 Ommo 1) was added dropwise, the mixture was stirred at room temperature for 1 hour. After the reaction solution was concentrated under reduced pressure, the concentrate was acidified with concentrated hydrochloric acid under ice-cooling. Extraction was performed with ethyl acetate (200 ml ⁇ 4), black-mouthed form (10 Oml ⁇ 2), and 5% methanol / black-mouthed form (250 ml ⁇ 2). The combined organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain 89 g (quantitative) of the title compound as a colorless oil.
- Getylphosphonoacetic acid (15.1 g, 76.8 mmo 1) was dissolved in anhydrous tetrahydrofuran (120 ml), and 1,1'-carbodidiimidazole (13.7 g, 84.5 mmo 1) was added under ice-cooling. After the addition, the mixture was stirred at room temperature for 1 hour. The reaction mixture was cooled under ice-cooling with ethyl ethyl [2- [N- [1- (S) -phenylethyl] amino] acetyl] cyclopropanecarboxylate (17.6 g, 64.
- Getylphosphonoacetic acid (32.8 g, 166 mmo 1) was dissolved in anhydrous benzene (70 Oml), N, N, monodimethylformamide (1 ml) was added, and then thionyl chloride (18.2 ml, 25 Ommo 1) was added. The mixture was refluxed for 1.5 hours. The reaction solution was allowed to cool, concentrated under reduced pressure, dried toluene (100 ml) was added, and further concentrated under reduced pressure.
- the aqueous layer was acidified with concentrated hydrochloric acid under ice-cooling, and extracted with black-mouthed form (70 ml X 3).
- the organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain 9.40 g (99%) of the title compound as a white solid.
- reaction solution was cooled to room temperature, tertiary butyl alcohol (95 ml) was added, and the mixture was heated under reflux for 15 hours. After allowing the reaction solution to cool, the mixture was concentrated under reduced pressure, and ethyl acetate (95 ml) and water (95 ml) were added to the concentrate. After the extraction operation, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (95 ml). The combined organic layer was washed with a saturated saline solution (95 ml) and dried over anhydrous sodium sulfate.
- Reference Example 36 1_benzyloxydicarbonyl 3 -— (R) - ⁇ — “N — (-grade butoxycarbonyl) -N- (methyl) amino—cyclopropyl, pyrrolidine 1 in a sealed tube protected from light Roxycarbone 3- (R) — [1- (tert-butoxycarbonylamino) cyclopropyl] pyrrolidine (1.40 g, 3.89 mmo 1), ⁇ , ⁇ '-dimethylformamide (7 ml), Sinidani silver (9.0 g, 39 mmo 1) and methyl iodide (24 ml, 389 mmo 1) were added, and the mixture was stirred in an oil bath at 80 ° C. for 13 hours.
- ⁇ -NM 400 MHz, CDC 1 3) ⁇ : 0. 73 (4 ⁇ , m), 1. 35 (9H, s), 1. 36 (3H, s), 1. 6 1 (1 H, m) , 1.85 (1H, m), 1.97 (lH, m), 2.27 (lH, m), 2.50-2.58 ( 2H, m), 2.79 (3H, s), 2.99 (lH, m), 3.14-3. 19 (1H, m), 7.27-7.30 (5H, m).
- reaction solution was cooled with ice, and the above solution A was added dropwise over 10 minutes.
- the solution A was washed into the reaction solution with tetrahydrofuran (10 ml), stirred for 14 hours at room temperature, and then poured into a 10% aqueous solution of citric acid (20 Oml). This was extracted with ethyl acetate (200 ml), washed with saturated saline (20 ml), and dried over anhydrous sodium sulfate. After the desiccant was removed by filtration, the solvent was distilled off under reduced pressure.
- a saturated aqueous sodium hydroxide solution was added to the aqueous layer after washing under ice-cooling to adjust the pH to> 11, and then concentrated hydrochloric acid and 1N hydrochloric acid were added to adjust the pH to 7.7.
- the slurry was purified with chill ether and dried under reduced pressure to obtain 96 mg (30%) of the title compound as a pale yellow powder.
- Example 17 7- "3- (R)-(1-aminocyclopropyl) pyrrolidine-1 !!-yl-1-1-1" 2- (S) -Fluoro-11- (R) -cyclopropyl-5 — Hydroxy-1-8-methyl-1,4, dihydro-4-oxoquinoline-13-carboxylic acid
- Example 18 7— “3- ()- ⁇ 1-aminocyclopropyl) pyrrolidine-1- 1-yl ⁇ —8-cyano 1—“ 2- (S) -fluoro-11- (R) -cyclopropyl ⁇ ⁇ — 1. 4-dihydro-4-oxoquinoline-1-carboxylic acid
- Example 19 7- "3- (R)-(1-aminocyclobutyl) pyrrolidine-1- 1-yl ⁇ —1—" 2- "2-fluoro-11-cyclopropyl ⁇ —8-methoxy-1-1.4 Dihydro-4-oxoquinoline 3-Contribution
- aqueous layer was added a 10N aqueous sodium hydroxide solution to adjust the pH to> 12 under ice-cooling, followed by addition of concentrated hydrochloric acid and 1N hydrochloric acid to adjust the pH to 7.4.
- the obtained aqueous layer was extracted with chloroform (100 ml ⁇ 3), and the combined organic layers were dried over anhydrous sodium sulfate. After the desiccant was removed by filtration, the solvent was distilled off under reduced pressure, and the residue was recrystallized from ethyl acetate hexane and dried under reduced pressure to obtain 99 mg (24%) of the title compound as a yellow powder.
- the obtained concentrate is dissolved in anhydrous tetrahydrofuran (20 Oml), and this solution is mixed with triethylamine (30 ml) and ethyl.
- a solution of 3-dimethylaminoacrylate (24.3 g, 17 Ommo 1) in anhydrous tetrahydrofuran (100 ml) was added dropwise with stirring under ice-cooling. After the addition was completed, the reaction solution was heated to reflux for 12 hours.
- the reaction mixture was filtered through celite (washed with ethyl acetate), the filtrate was concentrated under reduced pressure, and the obtained residue was subjected to short silica gel chromatography. Concentration gave a brown oil.
- the antibacterial activity of the compound of the present invention was measured in accordance with the standard method specified by the Japanese Society of Chemotherapy, and the results are shown in the following table in MIC (microgram Zml).
- MIC microgram Zml
- levofloxacin LVFX
- CP FX ciprofloxacin
- PCT / JP 96/00208 7- [3- (R)-(1 —Aminocyclopropyl) pyrrolidine-1-yl] -1-6-fluoro-11- [2- (S) -fluoro-1- (R) —cyclopropyl] -1-methyl-1--1,4-dihydro-1-oxoquinoline
- the MIC value of 3-carboxylic acid (Control 1) is also shown.
- Example 1 Example 2 Example 3 Example 1 0 Example 1
- Ser marcescens 10 100 0.025 0.1 0 0k 5 0.0R 0 2
- Example 1 of the present invention For the compound described in Example 1 of the present invention, a mouse bone marrow micronucleus test was performed by the method described below.
- a 0.1 mM 1/1 NaOH / saline solvent was used, and as a positive control drug, a drug solution obtained by dissolving and diluting cyclophosphamides (CP) with a saline was used. All were filtered and sterilized with a Myrex GS 0.22 m filter. Each drug solution was intravenously administered once at a dose rate of 10 ml / kg and 0.2 ml / min. Bone marrow cells were collected from the femur 24 hours after administration, smears were prepared, and stained with an acrylic range.
- CP cyclophosphamides
- Example 1 showed no significant difference in the micronucleus induction rate from the control in any of the 25, 50, and 100 mg / kg administration groups, and the judgment result was negative. . That is, it was found that the compound described in Example 1 had extremely low micronucleus inducing action and high safety.
- Example 1 of the present invention in which the 6-position fluorine of 1,4-dihydro-1-oxoquinoline-13-carboxylic acid was replaced by a hydrogen atom, was obtained by using Gram-negative bacteria and Gram-positive bacteria including resistant bacteria. It has been found that it has a wide range of strong antibacterial activity against any of them and has high safety.
- Example 1 of the present invention the blood concentration and organ concentration after oral administration were determined by the methods described below. The same method was used to measure control drug 1.
- test substance was prepared by dissolving the test substance in distilled water for injection to a concentration of Smg / ml (converted to free form), and using a 2.5 ml disposable syringe and a metal oral probe. It was orally administered to a fasting rat (Crj: CD IGS; male; 7 weeks old; Nippon Chillers River) at a dose of 2 Omg / kg.
- the excretion test group (4 animals per group) was placed in a metabolic cage after administration of the drug, and urine collected for 0 to 4 hours and 4 to 24 hours was collected under ice-cooling, and about 15 ml was collected in the cage at the time of sampling.
- the cells were washed with 0.1 mM phosphate buffer (pH 7.0), and the urine attached to the cage was collected.
- conjugates such as glucuronide
- a part of the sample was taken, hydrolyzed with an equal volume of lmo 1/1 sodium hydroxide aqueous solution, and then neutralized with 0.5 mo 1-hydrochloric acid. was also measured.
- Method 2 mm m ⁇
- the drug concentration in the liquid sample was determined by an agar-well method bioassay using B. subtilis ATCC6051 as a test bacterium.
- the suspension containing 5 ⁇ 10 7 CFU / m1 of the test bacterial spores was sterilized at 121 ° C for 15 minutes, and then inoculated at 1% on a normal agar medium (Eiken Chemical) cooled to about 50 ° C.
- the medium was used as an assay medium. This was dispensed into a sterile petri dish by 10 ml each, and after horizontal solidification, 4 holes of 8 mm diameter were punched to prepare a plate medium for assay.
- Bio-Assy System TDA-1 (Dainippon Seiki) was used.
- the test sample (diluted with serum or phosphate buffer as necessary), a drug dilution series for the calibration curve (two-fold serial dilution prepared so that the blocking circle diameter is about 10 to 30 mm)
- a reference solution (a solution of a known concentration to correct the difference between the plates, usually using a concentration that forms an inhibition circle of about 20 mm) is prepared, and the test sample (or The reference solution was injected into the remaining two wells by 50 ⁇ 1 each.
- the sample was allowed to stand at 4 ° C for 1 hour to perform pre-diffusion, then cultured at 37 ° C for about 18 hours, and the inhibition circle diameter was measured with CA-400 (Dainippon Seiki).
- the concentration of the test sample was calculated using a calibration curve obtained by quadratic regression from the logarithmic value of the drug concentration in the calibration curve dilution series and the diameter of the inhibition circle.
- the concentration in tissue was determined by the following formula based on the concentration of homogenate supernatant (zgZml) and the amount of phosphate buffer (ml) added to the tissue weight (g).
- [Tissue concentration] [homogenate concentration] X ([tissue weight] + [buffer volume]) / Urinary excretion rate (%) refers to drug dose (/ g), urine (or washing solution) volume ( ml) and the concentration in urine (or washing solution) (ug / ml) by the following formula.
- the pharmacokinetic parameters of each drug in rats were determined by using the pharmacokinetic analysis software P SAG—CP (asmide force) based on the average concentration transition, and using a model-independent method. It was calculated by the method.
- the serum concentrations of the compound of Example 1 and the control drug 1 and the concentrations in the organs of liver HHoi (9 vdl 9S, -kidney and lung) determined by the above method are shown in Table 2.
- the IPA of alcohol is isopropyl alcohol.
- the compound of the present invention has a broad and excellent antibacterial activity against both Gram-negative bacteria and Gram-positive bacteria, and is particularly useful for methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant pneumococcus (PRSP), and vancomycin. It shows strong antibacterial activity against resistant Gram-positive bacteria such as resistant enterococci (VRE) and quino-toxin-resistant bacteria, as well as excellent safety, such as negative micronucleus test, and urinary recovery. It also has excellent pharmacokinetics, such as an improved rate of absorption and excellent oral absorption, as well as excellent transfer to the organs from the blood, and is useful as an antibacterial compound used in chemotherapy for bacterial infections.
- MRSA methicillin-resistant Staphylococcus aureus
- PRSP penicillin-resistant pneumococcus
- vancomycin vancomycin
- It shows strong antibacterial activity against resistant Gram-positive bacteria such as resistant enterococci (VRE) and quino-toxin-resistant bacteria, as
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01996540A EP1336611B1 (en) | 2000-11-20 | 2001-11-19 | Dehalogeno compounds |
MXPA03004437A MXPA03004437A (es) | 2000-11-20 | 2001-11-19 | Compuestos de deshalogeno. |
CA002429440A CA2429440C (en) | 2000-11-20 | 2001-11-19 | Dehalogeno-compounds |
KR1020037006835A KR100777149B1 (ko) | 2000-11-20 | 2001-11-19 | 데할로게노 화합물 |
JP2002543488A JP3711108B2 (ja) | 2000-11-20 | 2001-11-19 | デハロゲノ化合物 |
DE60130359T DE60130359T2 (de) | 2000-11-20 | 2001-11-19 | Deshalogenverbindungen |
BR0115326-9A BR0115326A (pt) | 2000-11-20 | 2001-11-19 | Compostos dehalogenados |
IL15597601A IL155976A0 (en) | 2000-11-20 | 2001-11-19 | Dehalogeno compounds |
US10/432,043 US20040063754A1 (en) | 2000-11-20 | 2001-11-19 | Dehalogeno compounds |
AU2405002A AU2405002A (en) | 2000-11-20 | 2001-11-19 | Dehalogeno compounds |
NO20032255A NO326157B1 (no) | 2000-11-20 | 2003-05-19 | Dehalogen-forbindelse, antibakterielt middel omfattende denne, samt dens anvendelse |
IL155976A IL155976A (en) | 2000-11-20 | 2003-05-19 | Dehalogeno compounds |
HK03109128A HK1056729A1 (en) | 2000-11-20 | 2003-12-15 | Dehalogeno compounds |
US11/644,901 US7902226B2 (en) | 2000-11-20 | 2006-12-26 | Dehalogeno-compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-352269 | 2000-11-20 | ||
JP2000352269 | 2000-11-20 | ||
JP2001248822 | 2001-08-20 | ||
JP2001-248822 | 2001-08-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10432043 A-371-Of-International | 2001-11-19 | ||
US11/644,901 Continuation US7902226B2 (en) | 2000-11-20 | 2006-12-26 | Dehalogeno-compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002040478A1 true WO2002040478A1 (fr) | 2002-05-23 |
Family
ID=26604261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/010086 WO2002040478A1 (fr) | 2000-11-20 | 2001-11-19 | Composes dihalogenes |
Country Status (20)
Country | Link |
---|---|
US (2) | US20040063754A1 (ja) |
EP (1) | EP1336611B1 (ja) |
JP (3) | JP3711108B2 (ja) |
KR (1) | KR100777149B1 (ja) |
CN (1) | CN1269817C (ja) |
AR (1) | AR035599A1 (ja) |
AT (1) | ATE372338T1 (ja) |
AU (1) | AU2405002A (ja) |
BR (1) | BR0115326A (ja) |
CA (1) | CA2429440C (ja) |
DE (1) | DE60130359T2 (ja) |
ES (1) | ES2292642T3 (ja) |
HK (1) | HK1056729A1 (ja) |
IL (2) | IL155976A0 (ja) |
MX (1) | MXPA03004437A (ja) |
MY (1) | MY136916A (ja) |
NO (1) | NO326157B1 (ja) |
PT (1) | PT1336611E (ja) |
TW (1) | TWI315308B (ja) |
WO (1) | WO2002040478A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004108680A1 (ja) * | 2003-06-06 | 2004-12-16 | Daiichi Pharmaceutical Co., Ltd. | 光学活性なキノロンカルボン酸誘導体の製造中間体およびその製造法 |
WO2004113321A1 (ja) * | 2003-06-19 | 2004-12-29 | Daiichi Pharmaceutical Co., Ltd. | 選択的なアミノ置換基導入法 |
JP2005120067A (ja) * | 2003-09-22 | 2005-05-12 | Dai Ichi Seiyaku Co Ltd | 光学活性シクロプロピルアミン誘導体およびその製造方法 |
WO2005056526A1 (ja) * | 2003-12-12 | 2005-06-23 | Daiichi Pharmaceutical Co., Ltd. | 光学活性なシクロプロピルアミン誘導体の製造中間体およびその製造法 |
WO2006004028A1 (ja) * | 2004-07-02 | 2006-01-12 | Daiichi Pharmaceutical Co., Ltd. | キノロン含有医薬組成物 |
WO2007037330A1 (ja) * | 2005-09-28 | 2007-04-05 | Daiichi Sankyo Company, Limited | キノロン含有凍結乾燥製剤の製造方法 |
JP2008231067A (ja) * | 2007-03-23 | 2008-10-02 | Dai Ichi Seiyaku Co Ltd | キノロン含有凍結乾燥製剤の製造方法 |
US7723524B2 (en) | 2003-09-29 | 2010-05-25 | Daiichi Pharmaceutical Co., Ltd. | 8-cyanoquinolonecarboxylic acid derivative |
CN103059106A (zh) * | 2006-08-11 | 2013-04-24 | 北方抗生素有限公司 | 多粘菌素衍生物及其用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2429440C (en) | 2000-11-20 | 2009-12-29 | Daiichi Pharmaceutical Co., Ltd. | Dehalogeno-compounds |
CN100441580C (zh) * | 2006-07-14 | 2008-12-10 | 中山大学 | 喹啉二酮衍生物及其在制备抗菌药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999014214A1 (en) * | 1997-09-15 | 1999-03-25 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0207420B1 (en) * | 1985-06-26 | 1992-05-06 | Daiichi Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivatives |
DE69531305T2 (de) * | 1994-10-20 | 2004-05-13 | Wakunaga Seiyaku K.K. | Pyridoncarboxylat- derivate oder salze davon und antibakterielle zusammensetzungen die diese als aktiven bestandteil enthalten |
CA2212007C (en) * | 1995-02-02 | 2004-09-14 | Daiichi Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivatives substitued by a bicyclic amino group |
EP0992501B1 (en) * | 1995-09-22 | 2002-08-28 | Wakunaga Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivatives as antibacterial agents |
CN1119343C (zh) | 1995-11-22 | 2003-08-27 | 第一制药株式会社 | 取代的氨基环烷基吡咯烷衍生物 |
US6121285A (en) * | 1995-11-22 | 2000-09-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted aminocycloalkylpyrrolidine derivatives and cis-substituted aminocycloalkylpyrrolidine derivatives |
US6391889B2 (en) * | 1996-07-12 | 2002-05-21 | Daiichi Pharmaceutical Co., Ltd. | Cis-substituted aminocyclopropane derivatives |
JPH1081682A (ja) | 1996-07-12 | 1998-03-31 | Dai Ichi Seiyaku Co Ltd | シス置換アミノシクロプロパン誘導体 |
TW519542B (en) * | 1996-09-27 | 2003-02-01 | Daiichi Seiyaku Co | Bicyclic amine derivative |
IL132982A0 (en) * | 1997-05-21 | 2001-03-19 | Daiichi Seiyaku Co | Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives |
MY119816A (en) | 1997-05-30 | 2005-07-29 | Daiichi Seiyaku Co | Substituted cyclobutylamine derivatives |
KR20010014209A (ko) * | 1997-06-24 | 2001-02-26 | 스즈키 다다시 | 시스-치환된 플루오로메틸피롤리딘 유도체 |
JP2000023709A (ja) * | 1998-07-16 | 2000-01-25 | Shimano Inc | 長 靴 |
DE19834202A1 (de) | 1998-07-29 | 2000-02-10 | Coherent Luebeck Gmbh | Rauscharmer frequenzvervielfachter Laser mit Strahlseparator |
ATE297912T1 (de) | 1998-11-24 | 2005-07-15 | Daiichi Seiyaku Co | Cycloalkylsubstituierte aminomethylpyrrolidin- derivate |
CA2429440C (en) | 2000-11-20 | 2009-12-29 | Daiichi Pharmaceutical Co., Ltd. | Dehalogeno-compounds |
-
2001
- 2001-11-19 CA CA002429440A patent/CA2429440C/en not_active Expired - Fee Related
- 2001-11-19 AU AU2405002A patent/AU2405002A/xx not_active Withdrawn
- 2001-11-19 BR BR0115326-9A patent/BR0115326A/pt active Search and Examination
- 2001-11-19 PT PT01996540T patent/PT1336611E/pt unknown
- 2001-11-19 DE DE60130359T patent/DE60130359T2/de not_active Expired - Lifetime
- 2001-11-19 AR ARP010105401A patent/AR035599A1/es active IP Right Grant
- 2001-11-19 WO PCT/JP2001/010086 patent/WO2002040478A1/ja active IP Right Grant
- 2001-11-19 JP JP2002543488A patent/JP3711108B2/ja not_active Expired - Fee Related
- 2001-11-19 MX MXPA03004437A patent/MXPA03004437A/es active IP Right Grant
- 2001-11-19 EP EP01996540A patent/EP1336611B1/en not_active Expired - Lifetime
- 2001-11-19 AT AT01996540T patent/ATE372338T1/de active
- 2001-11-19 CN CNB018220746A patent/CN1269817C/zh not_active Expired - Fee Related
- 2001-11-19 KR KR1020037006835A patent/KR100777149B1/ko not_active IP Right Cessation
- 2001-11-19 US US10/432,043 patent/US20040063754A1/en not_active Abandoned
- 2001-11-19 ES ES01996540T patent/ES2292642T3/es not_active Expired - Lifetime
- 2001-11-19 IL IL15597601A patent/IL155976A0/xx unknown
- 2001-11-20 MY MYPI20015301A patent/MY136916A/en unknown
- 2001-11-20 TW TW090128688A patent/TWI315308B/zh not_active IP Right Cessation
-
2003
- 2003-05-19 IL IL155976A patent/IL155976A/en not_active IP Right Cessation
- 2003-05-19 NO NO20032255A patent/NO326157B1/no not_active IP Right Cessation
- 2003-12-15 HK HK03109128A patent/HK1056729A1/xx not_active IP Right Cessation
-
2004
- 2004-05-26 JP JP2004156517A patent/JP2004269544A/ja active Pending
- 2004-12-28 JP JP2004379455A patent/JP3760172B2/ja not_active Expired - Fee Related
-
2006
- 2006-12-26 US US11/644,901 patent/US7902226B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999014214A1 (en) * | 1997-09-15 | 1999-03-25 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1632482A4 (en) * | 2003-06-06 | 2009-10-28 | Daiichi Seiyaku Co | INTERMEDIATES AND PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE QUINOLONECARBOXYLIC ACID DERIVATIVES |
US7915418B2 (en) | 2003-06-06 | 2011-03-29 | Daiichi Pharmaceutical Co., Ltd. | Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives |
WO2004108680A1 (ja) * | 2003-06-06 | 2004-12-16 | Daiichi Pharmaceutical Co., Ltd. | 光学活性なキノロンカルボン酸誘導体の製造中間体およびその製造法 |
JPWO2004108680A1 (ja) * | 2003-06-06 | 2006-07-20 | 第一製薬株式会社 | 光学活性なキノロンカルボン酸誘導体の製造中間体およびその製造法 |
WO2004113321A1 (ja) * | 2003-06-19 | 2004-12-29 | Daiichi Pharmaceutical Co., Ltd. | 選択的なアミノ置換基導入法 |
JP4616770B2 (ja) * | 2003-06-19 | 2011-01-19 | 第一三共株式会社 | 選択的なアミノ置換基導入法 |
JPWO2004113321A1 (ja) * | 2003-06-19 | 2006-07-27 | 第一製薬株式会社 | 選択的なアミノ置換基導入法 |
JP4629973B2 (ja) * | 2003-09-22 | 2011-02-09 | 第一三共株式会社 | 光学活性シクロプロピルアミン誘導体およびその製造方法 |
JP2005120067A (ja) * | 2003-09-22 | 2005-05-12 | Dai Ichi Seiyaku Co Ltd | 光学活性シクロプロピルアミン誘導体およびその製造方法 |
US7723524B2 (en) | 2003-09-29 | 2010-05-25 | Daiichi Pharmaceutical Co., Ltd. | 8-cyanoquinolonecarboxylic acid derivative |
JP4619952B2 (ja) * | 2003-09-29 | 2011-01-26 | 第一三共株式会社 | 8−シアノキノロンカルボン酸誘導体 |
US7994344B2 (en) | 2003-12-12 | 2011-08-09 | Daiichi Sankyo Company, Limited | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates |
US7569599B2 (en) | 2003-12-12 | 2009-08-04 | Daiichi Pharmaceutical Co., Ltd. | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates |
WO2005056526A1 (ja) * | 2003-12-12 | 2005-06-23 | Daiichi Pharmaceutical Co., Ltd. | 光学活性なシクロプロピルアミン誘導体の製造中間体およびその製造法 |
WO2006004028A1 (ja) * | 2004-07-02 | 2006-01-12 | Daiichi Pharmaceutical Co., Ltd. | キノロン含有医薬組成物 |
JPWO2006004028A1 (ja) * | 2004-07-02 | 2008-04-24 | 第一製薬株式会社 | キノロン含有医薬組成物 |
WO2007037330A1 (ja) * | 2005-09-28 | 2007-04-05 | Daiichi Sankyo Company, Limited | キノロン含有凍結乾燥製剤の製造方法 |
US8129533B2 (en) | 2005-09-28 | 2012-03-06 | Dalichi Sankyo Company, Limited | Method for production of quinolone-containing lyophilized preparation |
CN103059106A (zh) * | 2006-08-11 | 2013-04-24 | 北方抗生素有限公司 | 多粘菌素衍生物及其用途 |
CN103059106B (zh) * | 2006-08-11 | 2015-01-14 | 北方抗生素有限公司 | 多粘菌素衍生物及其用途 |
JP2008231067A (ja) * | 2007-03-23 | 2008-10-02 | Dai Ichi Seiyaku Co Ltd | キノロン含有凍結乾燥製剤の製造方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7902226B2 (en) | Dehalogeno-compounds | |
KR101118402B1 (ko) | 5-하이드록시메틸-옥사졸리딘-2-원 유도체 | |
JPH07300416A (ja) | 抗菌性医薬 | |
JP3268098B2 (ja) | 二環性環状アミン誘導体 | |
KR100531967B1 (ko) | 트리사이클릭 아민 유도체, 이를 포함하는 항균제 및 퀴놀론 화합물의 제조방법 | |
JPH05163244A (ja) | ピリドンカルボン酸誘導体 | |
EP0995744B1 (en) | Cis-substituted fluoromethylpyrrolidine derivatives | |
WO2000031062A1 (fr) | Derives d'aminomethylpyrrolidine substitues par des cycloalkyles | |
WO2000053594A1 (fr) | Derives aminomethylpyrrolidine possedant des substituants aromatiques | |
WO1998054169A1 (fr) | Derives substitues de la cyclobutylamine | |
WO2005073238A1 (ja) | ピリドベンズオキサジン誘導体 | |
WO1998013370A1 (fr) | Derives de pyridobenzoxazine | |
RU2298006C2 (ru) | Дегалогенированные соединения, антибактериальное средство и терапевтическое средство на их основе, способ получения антибактериального или лекарственного средства, применение дегалогенированных соединений для получения антибактериального или лекарственного средства | |
JP4132155B2 (ja) | 三環性アミン誘導体 | |
JP4926723B2 (ja) | フルオロアルキルピロリジン誘導体 | |
JP4619952B2 (ja) | 8−シアノキノロンカルボン酸誘導体 | |
WO1998024781A1 (fr) | Derives d'aminomethylpyrrolidine substitue | |
WO2011091614A1 (zh) | 7-(2-取代-3-氨基-1-四氢吡咯[3,4-c]吡唑基)喹啉羧酸衍生物及其制备方法和在抗菌抗结核上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002543488 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 734/CHENP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/03871 Country of ref document: ZA Ref document number: 155976 Country of ref document: IL Ref document number: 10432043 Country of ref document: US Ref document number: 200303871 Country of ref document: ZA Ref document number: 1-2003-500392 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2429440 Country of ref document: CA Ref document number: 1020037006835 Country of ref document: KR Ref document number: PA/a/2003/004437 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001996540 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002224050 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018220746 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037006835 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001996540 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002224050 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001996540 Country of ref document: EP |